5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Activated clotting time value as an independent predictor of postoperative bleeding and transfusion

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          OBJECTIVES

          Activated clotting time (ACT) is commonly used to monitor anticoagulation during cardiac surgeries. Final ACT values may be essential to predict postoperative bleeding and transfusions, although ideal values remain unknown. Our aim was to evaluate the utility of ACT as a predictor of postoperative bleeding and transfusion use.

          METHODS

          Retrospective study (722 patients) submitted to surgery between July 2018–October 2021. We compared patients with final ACT < basal ACT and final ACT ≥ basal ACT and final ACT < 140 s with ≥140 s. Continuous variables were analysed with the Wilcoxon rank-sum test; categorical variables using Chi-square or Fisher's exact test. A linear mixed regression model was used to analyse bleeding in patients with final ACT < 140 and ≥140. Independent variables were analysed with binary logistic regression models to investigate their association with bleeding and transfusion.

          RESULTS

          Patients with final ACT ≥ 140 s presented higher postoperative bleeding than final ACT < 140 s at 12 h ( P = 0.006) and 24 h (** P = 0.004). Cardiopulmonary bypass (CPB) time [odds ratio (OR) 1.009, 1.002–1.015, 95% confidence interval (CI)] and masculine sex (OR 2.842,1.721–4.821, 95% CI) were significant predictors of bleeding. Patients with final ACT ≥ 140 s had higher risk of UT (OR 1.81, 1.13–2.89, 95% CI; P = 0.0104), compared to final ACT < 140 s. CPB time (OR 1.019,1.012–1.026, 95% CI) and final ACT (OR 1.021,1.010–1.032, 95% CI) were significant predictors of transfusion. Female sex was a predictor of use of transfusion, with a probability for use of 27.23% (21.84–33.39%, 95% CI) in elective surgeries, and 60.38% (37.65–79.36%, 95% CI) in urgent surgeries, higher than in males.

          CONCLUSIONS

          Final ACT has a good predictive value for the use of transfusion. Final ACT ≥ 140 s correlates with higher risk of transfusion and increased bleeding. The risk of bleeding and transfusion is higher with longer periods of CPB. Males have a higher risk of bleeding, but females have a higher risk of transfusion.

          Abstract

          Cardiac surgery carries a substantial risk of perioperative bleeding, due to the invasiveness of the procedure, the necessity for high-dose anticoagulation, the use of hypothermia and cardiopulmonary bypass (CPB) and the prevalent use of preoperative anticoagulants and antiplatelets medications, among other factors [1].

          Graphical Abstract

          Related collections

          Most cited references27

          • Record: found
          • Abstract: not found
          • Book: not found

          R: A language and environment for statistical computing

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found
            Is Open Access

            2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Gender differences in the effects of cardiovascular drugs.

              Although sex-specific differences in cardiovascular medicine are well known, the exact influences of sex on the effect of cardiovascular drugs remain unclear. Women and men differ in body composition and physiology (hormonal influences during the menstrual cycle, menopause, and pregnancy) and they present differences in drug pharmacokinetics (absorption, distribution, metabolism, and excretion) and pharmacodynamics, so that is not rare that they may respond differently to cardiovascular drugs. Furthermore, women are also less often treated with evidence-based drugs thereby preventing optimization of therapeutics for women of all ages, experience more relevant adverse drug reactions than men, and remain underrepresented in most clinical trials. Thus, current guidelines for prevention, diagnosis, and medical treatment for cardiovascular diseases are based on trials conducted predominantly in middle-aged men. A better understanding of these sex-related differences is fundamental to improve the safety and efficacy of cardiovascular drugs and for developing proper individualized cardiovascular therapeutic strategies both in men and women. This review briefly summarizes gender differences in the pharmacokinetics and pharmacodynamics of cardiovascular drugs and provides recommendations to close the gaps in our understanding of sex-specific differences in drug efficacy and safety.
                Bookmark

                Author and article information

                Contributors
                Journal
                Interdiscip Cardiovasc Thorac Surg
                Interdiscip Cardiovasc Thorac Surg
                icvts
                Interdisciplinary Cardiovascular and Thoracic Surgery
                Oxford University Press
                2753-670X
                May 2024
                08 May 2024
                08 May 2024
                : 38
                : 5
                : ivae092
                Affiliations
                Department of Cardiothoracic Surgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Escola Superior Saúde da Cruz Vermelha Portuguesa , Lisbon, Portugal
                Faculdade de Medicina da Universidade de Lisboa , Lisbon, Portugal
                Department of Cardiothoracic Surgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Transfusion Medicine Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Transfusion Medicine Department, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Department of Cardiothoracic Surgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa , Lisbon, Portugal
                Centro Cardiovascular da Universidade de Lisboa, Faculdade de Medicina, Universidade de Lisboa , Lisbon, Portugal
                Department of Cardiology, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian de Ciência , Oeiras, Portugal
                Department of Cardiothoracic Surgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon, Portugal
                Innate Immunity and Inflammation Laboratory, Instituto Gulbenkian de Ciência , Oeiras, Portugal
                Cardiothoracic Surgery Research Unit, Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE), Faculdade de Medicina da Universidade de Lisboa , Lisbon, Portugal
                Author notes

                Rafael Maniés Pereira and Diogo Magueijo authors contributed equally to this work.

                Corresponding author. Department of Cardiothoracic Surgery, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Av. Prof. Egas Moniz, 1649-028, Lisbon, Portugal. Tel: +351217805000; e-mail: tiagovelho48@ 123456hotmail.com (T.R. Velho).
                Author information
                https://orcid.org/0000-0002-9604-1223
                https://orcid.org/0000-0003-0707-315X
                https://orcid.org/0000-0002-0455-8189
                Article
                ivae092
                10.1093/icvts/ivae092
                11109492
                38718163
                c65ca84d-b93f-4337-a640-76443d19cc03
                © The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 06 February 2024
                : 13 March 2024
                : 07 May 2024
                : 21 May 2024
                Page count
                Pages: 10
                Categories
                General Interest
                Original Article
                Eacts/118
                Eacts/105
                AcademicSubjects/MED00920

                activated clotting time,bleeding,cardiac surgery,cardiopulmonary bypass,postoperative,transfusion

                Comments

                Comment on this article